Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282432 · ClinicalTrials.gov registry record
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
A clinical trial of Leukocyte Adhesion Deficiency, sponsored by Rocket Pharmaceuticals.
- Active
- Registry status
- 9
- Enrollment target
- 3
- Study locations
NCT06282432: Active study of Leukocyte Adhesion Deficiency, sponsored by Rocket Pharmaceuticals.
NCT06282432 is a study of Leukocyte Adhesion Deficiency that is active but no longer recruiting, run by Rocket Pharmaceuticals. The registered enrollment target is 9 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06282432, a study of Leukocyte Adhesion Deficiency, is active but no longer recruiting, sponsored by Rocket Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene
Primary Outcome
Survival without allogeneic-HSCT.
Conditions Studied
Study Locations (3)
Other
- Hospital Infantil Universitario Niño Jesús - Madrid
- University College London Great Ormond Street Institute of Child Health (GOSH) - London
California
- University of California, Los Angeles (UCLA) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2036-10-04 |
What the registry record for NCT06282432 still lists
NCT06282432 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 1 condition, with Leukocyte Adhesion Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT06282432 reports a single indexed study location in Other, California.
Frequently Asked Questions
What is clinical trial NCT06282432 about?
NCT06282432 is a clinical study titled "Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)". This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene
What is the current status of trial NCT06282432?
This trial is currently active not recruiting. The enrollment target is 9 participants. The study started on 2022-03-09. Estimated completion is 2036-10-04.
What conditions does trial NCT06282432 study?
This clinical trial studies the following conditions: Leukocyte Adhesion Deficiency.
Who is sponsoring clinical trial NCT06282432?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06282432 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukocyte Adhesion Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI